RxDoctor Payments Data

Amanda Cieluch, APRN

Gerontology · Florence, SCNPI 1659086205

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 26.0% of the total. 2025 is the largest year on record at $1,125, 2.9 times the $383 reported in 2023.

$2,085in general payments, 2019–2025

Across 137 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$542
  • Novo Nordisk$281
  • Lilly USA, LLC$253
  • GSK$213
  • AstraZeneca$114
  • Dexcom, Inc.$82
  • plus $599 from 17 others

What the payments were for

  • Food & beverage$2,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,085 in reported general payments places this provider in the 70th percentile of 137 gerontology providers in South Carolina.

See all gerontology providers in South Carolina

Medicare billing

Part B allowed, 2024
$958
Medicare patients
33
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide87$117,401
JardianceEmpagliflozin129$113,083
OzempicSemaglutide62$68,229
LinzessLinaclotide90$66,175
JanuviaSitagliptin Phosphate52$52,657
TrulicityDulaglutide18$34,656
RybelsusSemaglutide27$28,037
MyrbetriqMirabegron31$23,396
Breo ElliptaFluticasone/Vilanterol43$20,976
FarxigaDapagliflozin Propanediol35$18,739
EliquisApixaban24$18,382
Janumet XrSitagliptin Phos/Metformin Hcl18$16,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,102
Tresiba Flextouch U-100Insulin Degludec27$13,321
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$253$152,057105 claims
Boehringer IngelheimJardiance$29$113,083129 claims
Novo NordiskOzempic, Rybelsus$281$96,26689 claims
AbbVieLinzess$542$66,17590 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$213$43,16982 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$114$39,62580 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 137 gerontology providers in South Carolina.

Other gerontology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →